Arcadia Biosciences (RKDA) Company Report

Arcadia Biosciences, Inc. (RKDA) announced that it has entered into definitive agreements for the immediate exercise of certain outstanding preferred investment options, which are expected to generate approximately $2.1 million in gross proceeds.
The exercise involved 808,595 shares at a reduced exercise price of $2.575 per share, compared to their original exercise price of $9.00 per share.
In consideration for the immediate exercise, Arcadia will issue new unregistered preferred investment options to purchase up to 1,617,190 shares of common stock, with an exercise price of $2.325 per share.
The company intends to use the net proceeds from this offering for working capital and general corporate purposes.

Jan 14, 2026, 1:07 AM

Arcadia Biosciences Announces Exercise of Preferred Investment Options

RKDA

Convertible Preferred Issuance

Arcadia Biosciences (RKDA) has entered into definitive agreements for the immediate exercise of certain outstanding preferred investment options, originally issued between December 2020 and March 2023.
The exercise involves up to 808,595 shares at a reduced exercise price of $2.575 per share (down from $9.00).
The company expects to receive approximately $2.1 million in gross proceeds from this exercise.
In consideration for the immediate exercise, Arcadia will issue new unregistered preferred investment options to purchase up to 1,617,190 shares of common stock, with an exercise price of $2.325 per share.
The net proceeds from the offering are intended for working capital and general corporate purposes.

Jan 12, 2026, 1:00 PM

Arcadia Biosciences Announces Q3 2025 Financial Results

RKDA

Earnings

M&A

Revenue Acceleration/Inflection

Arcadia Biosciences (RKDA) reported total revenues of $1.302 million for the third quarter ended September 30, 2025, representing a 15% decrease compared to the same period in 2024, primarily due to the absence of GLA oil sales in 2025 and a large initial sell-in of Zola® in Q3 2024. However, year-to-date revenues increased 3% to $3.957 million.
The company achieved net income attributable to common stockholders of $856,000 ($0.63 per share) for Q3 2025, a $2.5 million improvement from a net loss of $1.612 million ($1.18 per share) in Q3 2024. This improvement was primarily driven by $1.7 million in other income related to an unrealized gain on Above Food Ingredients Inc. common stock.
Gross profit margins exceeded 30% for the eleventh consecutive quarter.
The company's cash balance declined by only $257,000 to $1.1 million as of September 30, 2025.
Zola® year-to-date revenues increased 26% year-over-year. The pending business combination with Roosevelt Resources faces timing uncertainty due to an ongoing federal government shutdown.